As we head into the final 90 minutes of the trading session, these are today’s top stock gainers:
It seems like Lantheus Holdings (NASDAQ:LNTH) is the only one of the bunch with a concrete catalyst for today’s move. In fact, the Centers for Medicare and Medicaid Services put out a draft proposal to improve payments to diagnostic radiopharmaceuticals, which could potentially increase payments to the company’s prostate cancer imaging agent, Pylarify.
For the full list of top gainers, as well as the lists of Top Losers and Most Active stocks, click here.
Is LNTH Stock a Buy?
Turning to Wall Street, analysts have a Strong Buy consensus rating on LNTH stock based on six Buys assigned in the past three months, as indicated by the graphic below. After a 70% year-to-date rally, the average LNTH price target of $106.75 per share implies 37.39% upside potential.
